• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基因组失衡确定了肾母细胞瘤中的潜在癌基因和肿瘤抑制基因。

Genomic imbalances pinpoint potential oncogenes and tumor suppressors in Wilms tumors.

作者信息

Krepischi A C V, Maschietto M, Ferreira E N, Silva A G, Costa S S, da Cunha I W, Barros B D F, Grundy P E, Rosenberg C, Carraro D M

机构信息

International Research Center, AC Camargo Cancer Center, São Paulo, Brazil.

Institute of Biosciences, University of São Paulo, São Paulo, Brazil.

出版信息

Mol Cytogenet. 2016 Feb 24;9:20. doi: 10.1186/s13039-016-0227-y. eCollection 2016.

DOI:10.1186/s13039-016-0227-y
PMID:26913079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4765068/
Abstract

BACKGROUND

Wilms tumor (WT) has a not completely elucidated pathogenesis. DNA copy number alterations (CNAs) are common in cancer, and often define key pathogenic events. The aim of this work was to investigate CNAs in order to disclose new candidate genes for Wilms tumorigenesis.

RESULTS

Array-CGH of 50 primary WTs without pre-chemotherapy revealed a few recurrent CNAs not previously reported, such as 7q and 20q gains, and 7p loss. Genomic amplifications were exclusively detected in 3 cases of WTs that later relapsed, which also exhibited an increased frequency of gains affecting a 16.2 Mb 1q21.1-q23.2 region, losses at 11p, 11q distal, and 16q, and WT1 deletions. Conversely, aneuploidies of chromosomes 13 and 19 were found only in WTs without further relapse. The 1q21.1-q23.2 gain associated with WT relapse harbours genes such as CHD1L, CRABP2, GJA8, MEX3A and MLLT11 that were found to be over-expressed in WTs. In addition, down-regulation of genes encompassed by focal deletions highlighted new potential tumor suppressors such as CNKSR1, MAN1C1, PAQR7 (1p36), TWIST1, SOSTDC1 (7p14.1-p12.2), BBOX and FIBIN (11p13), and PLCG2 (16q).

CONCLUSION

This study confirmed the presence of CNAs previously related to WT and characterized new CNAs found only in few cases. The later were found in higher frequency in relapsed cases, suggesting that they could be associated with WT progression.

摘要

背景

肾母细胞瘤(WT)的发病机制尚未完全阐明。DNA拷贝数改变(CNA)在癌症中很常见,并且常常定义关键的致病事件。本研究旨在调查CNA,以揭示肾母细胞瘤发生的新候选基因。

结果

对50例未经化疗的原发性WT进行的阵列比较基因组杂交(Array-CGH)显示了一些先前未报道的复发性CNA,如7q和20q增益以及7p缺失。仅在3例后来复发的WT病例中检测到基因组扩增,这些病例还表现出影响16.2 Mb的1q21.1-q23.2区域的增益频率增加、11p、11q远端和16q缺失以及WT1缺失。相反,仅在未进一步复发的WT中发现了13号和19号染色体的非整倍体。与WT复发相关的1q21.1-q23.2增益区域包含CHD1L、CRABP2、GJA8、MEX3A和MLLT11等基因,这些基因在WT中被发现过度表达。此外,局灶性缺失所包含基因的下调突出了新的潜在肿瘤抑制因子,如CNKSR1、MAN1C1、PAQR7(1p36)、TWIST1、SOSTDC1(7p14.1-p12.2)、BBOX和FIBIN(11p13)以及PLCG2(16q)。

结论

本研究证实了先前与WT相关的CNA的存在,并对仅在少数病例中发现的新CNA进行了特征描述。后者在复发病例中出现的频率更高,表明它们可能与WT进展有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4665/4765068/6c60b9cf7b41/13039_2016_227_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4665/4765068/7d21b5d47bdb/13039_2016_227_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4665/4765068/b427d6f7b349/13039_2016_227_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4665/4765068/6c60b9cf7b41/13039_2016_227_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4665/4765068/7d21b5d47bdb/13039_2016_227_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4665/4765068/b427d6f7b349/13039_2016_227_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4665/4765068/6c60b9cf7b41/13039_2016_227_Fig3_HTML.jpg

相似文献

1
Genomic imbalances pinpoint potential oncogenes and tumor suppressors in Wilms tumors.基因组失衡确定了肾母细胞瘤中的潜在癌基因和肿瘤抑制基因。
Mol Cytogenet. 2016 Feb 24;9:20. doi: 10.1186/s13039-016-0227-y. eCollection 2016.
2
Copy number alterations in small intestinal neuroendocrine tumors determined by array comparative genomic hybridization.通过阵列比较基因组杂交确定小肠神经内分泌肿瘤中的拷贝数改变。
BMC Cancer. 2013 Oct 29;13:505. doi: 10.1186/1471-2407-13-505.
3
Analysis of wilms tumors using SNP mapping array-based comparative genomic hybridization.应用 SNP 图谱比较基因组杂交技术分析肾母细胞瘤。
PLoS One. 2011 Apr 22;6(4):e18941. doi: 10.1371/journal.pone.0018941.
4
Combined Genetic and Chromosomal Characterization of Wilms Tumors Identifies Chromosome 12 Gain as a Potential New Marker Predicting a Favorable Outcome.联合遗传学和染色体特征分析鉴定出 Wilms 肿瘤中染色体 12 的增益可能是预测良好预后的新标记物。
Neoplasia. 2019 Jan;21(1):117-131. doi: 10.1016/j.neo.2018.10.007. Epub 2018 Dec 6.
5
Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors.WT1野生型和WT1突变型肾母细胞瘤的全基因组杂合性缺失分析
Genes Chromosomes Cancer. 2005 Jun;43(2):172-80. doi: 10.1002/gcc.20169.
6
Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.组织学类型良好的肾母细胞瘤的阵列比较基因组杂交分析揭示了与复发相关的新的染色体增减。
J Pathol. 2006 Sep;210(1):49-58. doi: 10.1002/path.2021.
7
Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor.在肾母细胞瘤的7p21纯合缺失区域中鉴定出的两个候选肿瘤抑制基因,即MEOX2和SOSTDC1。
Genes Chromosomes Cancer. 2009 Dec;48(12):1037-50. doi: 10.1002/gcc.20705.
8
Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women.年轻白人和非裔美国女性浸润性乳腺癌亚型的全基因组拷贝数改变。
Breast Cancer Res Treat. 2011 May;127(1):297-308. doi: 10.1007/s10549-010-1297-x. Epub 2011 Jan 25.
9
Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma.肝内胆管癌的染色体拷贝数改变模式
BMC Cancer. 2015 Mar 14;15:126. doi: 10.1186/s12885-015-1111-6.
10
Integration of transcript expression, copy number and LOH analysis of infiltrating ductal carcinoma of the breast.浸润性导管乳腺癌的转录表达、拷贝数和 LOH 分析的整合。
BMC Cancer. 2010 Aug 27;10:460. doi: 10.1186/1471-2407-10-460.

引用本文的文献

1
Gene Expression Analysis of (Paired) Primary and Relapsed Wilms Tumor Samples to Unravel the Underlying Factors Driving Tumor Recurrence.(配对的)原发性和复发性肾母细胞瘤样本的基因表达分析,以揭示驱动肿瘤复发的潜在因素。
Cancer Med. 2025 Jun;14(11):e70969. doi: 10.1002/cam4.70969.
2
PLCG2, A Regulator of Lung Adenocarcinoma Proliferation and Migration Associated with Immune Infiltration.PLCG2,一种与免疫浸润相关的肺腺癌增殖和迁移的调节因子。
Curr Cancer Drug Targets. 2025;25(2):159-169. doi: 10.2174/0115680096307100240801095132.
3
Methyltransferase DNMT3B promotes colorectal cancer cell proliferation by inhibiting PLCG2.

本文引用的文献

1
Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.在国际儿科肿瘤学会(SIOP)WT 2001试验中,1q增益作为术前化疗治疗的肾母细胞瘤(WTs)的预后生物标志物:一项SIOP肾肿瘤生物学联盟研究。
J Clin Oncol. 2016 Sep 10;34(26):3195-203. doi: 10.1200/JCO.2015.66.0001. Epub 2016 Jul 18.
2
Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.1号染色体长臂、3号和16号染色体的染色体异常以及SIX1和DROSHA基因的突变是肾母细胞瘤复发的基础。
Oncotarget. 2016 Feb 23;7(8):8908-15. doi: 10.18632/oncotarget.6950.
3
甲基转移酶DNMT3B通过抑制PLCG2促进结肠癌细胞增殖。
Acta Biochim Biophys Sin (Shanghai). 2024 Aug 7;56(12):1848-1859. doi: 10.3724/abbs.2024117.
4
Teratoma-associated and so-called pure Wilms tumour of the ovary represent two separate tumour types with distinct molecular features.畸胎瘤相关和所谓的卵巢单纯 Wilms 瘤是两种具有不同分子特征的独立肿瘤类型。
Histopathology. 2024 Mar;84(4):683-696. doi: 10.1111/his.15116. Epub 2023 Dec 12.
5
Genome-wide DNA methylation profiling of HPV-negative leukoplakia and gingivobuccal complex cancers.HPV 阴性口腔白斑和龈颊复合体癌的全基因组 DNA 甲基化分析。
Clin Epigenetics. 2023 May 27;15(1):93. doi: 10.1186/s13148-023-01510-z.
6
Molecular Characterization Reveals Subclasses of 1q Gain in Intermediate Risk Wilms Tumors.分子特征揭示了中危肾母细胞瘤中1q增益的亚类。
Cancers (Basel). 2022 Oct 5;14(19):4872. doi: 10.3390/cancers14194872.
7
Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.与良好组织学 Wilms 瘤复发相关的遗传变化:儿童肿瘤学组 AREN03B2 研究。
Cell Rep Med. 2022 Jun 21;3(6):100644. doi: 10.1016/j.xcrm.2022.100644. Epub 2022 May 25.
8
A risk model of gene signatures for predicting platinum response and survival in ovarian cancer.一种用于预测卵巢癌铂类药物反应和生存的基因标志物风险模型。
J Ovarian Res. 2022 Mar 31;15(1):39. doi: 10.1186/s13048-022-00969-3.
9
Chromodomain-helicase-DNA-binding protein 1-like (CHD1L) silencing inhibits gastric cancer cell proliferation, invasion, and migration.染色质结构域解旋酶DNA结合蛋白1样(CHD1L)沉默抑制胃癌细胞的增殖、侵袭和迁移。
Transl Cancer Res. 2020 Nov;9(11):6660-6671. doi: 10.21037/tcr-19-2700.
10
MicroRNA-139-5p Suppresses Cell Malignant Behaviors in Breast Cancer through Targeting MEX3A.miR-139-5p 通过靶向调控 MEX3A 抑制乳腺癌细胞的恶性行为
Comput Math Methods Med. 2021 Nov 2;2021:6591541. doi: 10.1155/2021/6591541. eCollection 2021.
Response to the letter to the editor: 1q gain is a frequent finding in preoperatively treated Wilms tumors, but of limited prognostic value for risk satisfaction in the SIOP2009/Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) trial.
致编辑信的回复:1q增益在术前治疗的肾母细胞瘤中是常见发现,但在SIOP2009/德国儿科肿瘤与血液学会(GPOH)试验中,其对风险评估的预后价值有限。
Genes Chromosomes Cancer. 2015 Jun;54(6):397-9. doi: 10.1002/gcc.22250. Epub 2015 Mar 28.
4
Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors.SIX1/2 通路和 DROSHA/DGCR8 miRNA 处理器复合物的突变是高危胚细胞瘤型肾母细胞瘤的基础。
Cancer Cell. 2015 Feb 9;27(2):298-311. doi: 10.1016/j.ccell.2015.01.002.
5
Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.复发性 DGCR8、DROSHA 和 SIX 同源域突变与良好组织学 Wilms 肿瘤相关。
Cancer Cell. 2015 Feb 9;27(2):286-97. doi: 10.1016/j.ccell.2015.01.003.
6
Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer.肿瘤内基因组多样性与儿科癌症的进展和预后相关。
Nat Commun. 2015 Jan 27;6:6125. doi: 10.1038/ncomms7125.
7
TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.TP53突变状态是弥漫性间变的肾母细胞瘤风险分层的潜在标志物。
PLoS One. 2014 Oct 14;9(10):e109924. doi: 10.1371/journal.pone.0109924. eCollection 2014.
8
Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours.在肾母细胞瘤中,DROSHA和DICER1的体细胞突变通过不同机制损害微小RNA的生物合成。
Nat Commun. 2014 Sep 5;2:4802. doi: 10.1038/ncomms5802.
9
1q gain is a frequent finding in preoperatively treated Wilms tumors, but of limited prognostic value for risk stratification in the SIOP2001/GPOH trial.1q 增益在术前治疗的肾母细胞瘤中是常见的发现,但在 SIOP2001/GPOH 试验中,其对风险分层的预后价值有限。
Genes Chromosomes Cancer. 2014 Nov;53(11):960-2. doi: 10.1002/gcc.22203. Epub 2014 Jul 18.
10
Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour.DROSHA基因中的复发性体细胞突变会诱导肾母细胞瘤中的微小RNA谱发生变化。
Nat Commun. 2014 Jun 9;5:4039. doi: 10.1038/ncomms5039.